Ascendis Pharma A/S announced that it has started enrollment for a Compassionate Use Program (CUP) in Germany for TransCon PTH (palopegteriparatide), an investigational prodrug designed to provide sustained release of active parathyroid hormone (PTH 1-34) within the physiological range for 24 hours per day in adult patients with hypoparathyroidism with once-daily administration. The CUP was approved by Germany's Federal Institute for Drugs & Medical Devices (Bundesinstitut fur Arzneimittel & Medizinprodukte, or BfArM). Through the CUP, treating physicians can request TransCon PTH (palOPegteriparatide) for eligible adult patients with Hypoparathyroidism whose clinical condition, in the opinion of the treating physician, requires PTH treatment with palopegteriparatide, and who cannot be adequately treated with currently approved products or participate in a palopegteriparatides clinical trial.